{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:02Z","timestamp":1792787942779,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Cancer Society","award":["KWF 12033"],"award-info":[{"award-number":["KWF 12033"]}],"id":[{"id":"https:\/\/ror.org\/0368jnd28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Health Holland Public-private partnership","award":["EMCLSH 20020"],"award-info":[{"award-number":["EMCLSH 20020"]}],"id":[{"id":"https:\/\/ror.org\/056cwr036","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02765-9","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:35:21Z","timestamp":1788777321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["T cell receptors equipped with ICOS provide T cells with durable anti-tumor response"],"prefix":"10.1186","volume":"25","author":[{"given":"Alexandre","family":"Marraffa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"Berrevoets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Mosiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui M.L.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Roelofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"van Brakel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kroese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies J.W.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem A.","family":"Dik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Kunert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.M.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Hammerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schliehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reno","family":"Debets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"25","key":"2765_CR1","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129\u201339. https:\/\/doi.org\/10.1182\/blood-2013-08-519413 . PubMed PMID: 24055823; PubMed Central PMCID: PMC3862276.","journal-title":"Blood"},{"issue":"177","key":"2765_CR2","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38. https:\/\/doi.org\/10.1126\/scitranslmed.3005930 . PubMed PMID: 23515080; PubMed Central PMCID: PMC3742551.","journal-title":"Sci Transl Med"},{"issue":"1","key":"2765_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980 . PubMed PMID: 30501490.","journal-title":"N Engl J Med"},{"issue":"8","key":"2765_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric Antigen Receptor\u2013Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med. 2011;365(8):725\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1103849.","journal-title":"N Engl J Med"},{"issue":"26","key":"2765_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"1","key":"2765_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7.\u00a0 PubMed PMID: 30518502.","journal-title":"Lancet Oncol"},{"key":"2765_CR7","doi-asserted-by":"publisher","first-page":"867013","DOI":"10.3389\/fimmu.2022.867013","volume":"13","author":"A Moretti","year":"2022","unstructured":"Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The Past, Present, and Future of Non-Viral CAR T Cells. Front Immunol. 2022;13:867013. https:\/\/doi.org\/10.3389\/fimmu.2022.867013 . PubMed PMID: 35757746; PubMed Central PMCID: PMC9218214.","journal-title":"Front Immunol"},{"issue":"24","key":"2765_CR8","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021;39(24):2656\u201366. https:\/\/doi.org\/10.1200\/JCO.21.00612 . PubMed PMID: 33979178; PubMed Central PMCID: PMC8376325.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2765_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, et al. Autologous T cell therapy for MAGE-A4\u2009+\u2009solid cancers in HLA-A*02\u2009+\u2009patients: a phase 1 trial. Nat Med. 2023;29(1):104\u201314. https:\/\/doi.org\/10.1038\/s41591-022-02128-z . PubMed PMID: 36624315; PubMed Central PMCID: PMC9873554.","journal-title":"Nat Med"},{"issue":"12","key":"2765_CR10","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s43018-024-00860-8","volume":"5","author":"RJ Kishton","year":"2024","unstructured":"Kishton RJ, Restifo NP. T cells lead the charge against solid tumors. Nat Cancer. 2024;5(12):1762\u20134. https:\/\/doi.org\/10.1038\/s43018-024-00860-8.","journal-title":"Nat Cancer"},{"issue":"1","key":"2765_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.smim.2016.03.002","volume":"28","author":"R Debets","year":"2016","unstructured":"Debets R, Donnadieu E, Chouaib S, Coukos G. TCR-engineered T cells to treat tumors: Seeing but not touching? Semin Immunol. 2016;28(1):10\u201321. https:\/\/doi.org\/10.1016\/j.smim.2016.03.002.\u00a0 PubMed PMID: 26997556.","journal-title":"Semin Immunol"},{"issue":"11","key":"2765_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.it.2018.09.004","volume":"39","author":"D Hammerl","year":"2018","unstructured":"Hammerl D, Rieder D, Martens JWM, Trajanoski Z, Debets R, Adoptive T. Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies. Trends Immunol. 2018;39(11):921\u201336. https:\/\/doi.org\/10.1016\/j.it.2018.09.004.","journal-title":"Trends Immunol"},{"issue":"1","key":"2765_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imr.12772","volume":"290","author":"SS Chandran","year":"2019","unstructured":"Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunol Rev. 2019;290(1):127\u201347. https:\/\/doi.org\/10.1111\/imr.12772 . PubMed PMID: 31355495; PubMed Central PMCID: PMC7027847.","journal-title":"Immunol Rev"},{"issue":"1","key":"2765_CR14","doi-asserted-by":"publisher","first-page":"926321","DOI":"10.1155\/2012\/926321","volume":"2012","author":"D Capece","year":"2012","unstructured":"Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting Costimulatory Molecules to Improve Antitumor Immunity. Biomed Res Int. 2012;2012(1):926321. https:\/\/doi.org\/10.1155\/2012\/926321.","journal-title":"Biomed Res Int"},{"issue":"23","key":"2765_CR15","doi-asserted-by":"publisher","first-page":"12848","DOI":"10.3390\/ijms252312848","volume":"25","author":"O Franzese","year":"2024","unstructured":"Franzese O. Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes. Int J Mol Sci. 2024;25(23):12848. https:\/\/doi.org\/10.3390\/ijms252312848.","journal-title":"Int J Mol Sci"},{"issue":"200","key":"2765_CR16","doi-asserted-by":"publisher","first-page":"ra200116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8\u2009+\u2009T Cells. Sci Transl Med. 2013;5(200):ra200116\u2013200116. https:\/\/doi.org\/10.1126\/scitranslmed.3006504.","journal-title":"Sci Transl Med"},{"issue":"1","key":"2765_CR17","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","volume":"13","author":"A Gyurdieva","year":"2022","unstructured":"Gyurdieva A, Zajic S, Chang YF, Houseman EA, Zhong S, Kim J, et al. Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. Nat Commun. 2022;13(1):5296. https:\/\/doi.org\/10.1038\/s41467-022-32491-x.","journal-title":"Nat Commun"},{"issue":"5795","key":"2765_CR18","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science. 2006;313(5795):1960\u20134. https:\/\/doi.org\/10.1126\/science.1129139.","journal-title":"Science"},{"issue":"1","key":"2765_CR19","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, Martens JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021;12(1):5668. https:\/\/doi.org\/10.1038\/s41467-021-25962-0.","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"2765_CR20","doi-asserted-by":"publisher","first-page":"10251","DOI":"10.1182\/blood-2022-168421","volume":"140","author":"E Moreno","year":"2022","unstructured":"Moreno E, Franco-Fuquen P, Forero JV, Garcia Robledo JE, Booth N, Castro JE. ICOS and OX40 Signaling Optimization Improves CAR-T Cell Persistence in Preclinical Models. Blood. 2022;140(Supplement 1):10251\u20132. https:\/\/doi.org\/10.1182\/blood-2022-168421.","journal-title":"Blood"},{"issue":"7","key":"2765_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","volume":"124","author":"S Guedan","year":"2014","unstructured":"Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells. Blood. 2014;124(7):1070\u201380. https:\/\/doi.org\/10.1182\/blood-2013-10-535245 . PubMed PMID: 24986688; PubMed Central PMCID: PMC4133482.","journal-title":"Blood"},{"issue":"4","key":"2765_CR22","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.4049\/jimmunol.170.4.2186","volume":"170","author":"N Schaft","year":"2003","unstructured":"Schaft N, Willemsen RA, de Vries J, Lankiewicz B, Essers BWL, Gratama JW, et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol. 2003;170(4):2186\u201394. https:\/\/doi.org\/10.4049\/jimmunol.170.4.2186 . PubMed PMID: 12574392.","journal-title":"J Immunol"},{"issue":"7","key":"2765_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/jgm.1047","volume":"9","author":"NMC Pouw","year":"2007","unstructured":"Pouw NMC, Westerlaken EJ, Willemsen RA, Debets R. Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes. J Gene Med. 2007;9(7):561\u201370. https:\/\/doi.org\/10.1002\/jgm.1047 . PubMed PMID: 17471588.","journal-title":"J Gene Med"},{"issue":"12","key":"2765_CR24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1089\/104303403322167993","volume":"14","author":"B Engels","year":"2003","unstructured":"Engels B, Cam H, Sch\u00fcler T, Indraccolo S, Gladow M, Baum C, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther. 2003;14(12):1155\u201368. https:\/\/doi.org\/10.1089\/104303403322167993 . PubMed PMID: 12908967.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"2765_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/mt.2014.215","volume":"23","author":"T Straetemans","year":"2015","unstructured":"Straetemans T, Berrevoets C, Coccoris M, Treffers-Westerlaken E, Wijers R, Cole DK, et al. Recurrence of Melanoma Following T Cell Treatment: Continued Antigen Expression in a Tumor That Evades T Cell Recruitment. Mol Ther. 2015;23(2):396\u2013406. https:\/\/doi.org\/10.1038\/mt.2014.215 . PubMed PMID: 25363716; PubMed Central PMCID: PMC4445618.","journal-title":"Mol Ther"},{"issue":"10","key":"2765_CR26","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.4049\/jimmunol.1302074","volume":"193","author":"C Govers","year":"2014","unstructured":"Govers C, Sebesty\u00e9n Z, Roszik J, van Brakel M, Berrevoets C, Sz\u00f6\u0151r \u00c1, et al. TCRs genetically linked to CD28 and CD3\u03b5 do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity. J Immunol. 2014;193(10):5315\u201326. https:\/\/doi.org\/10.4049\/jimmunol.1302074 . PubMed PMID: 25320284.","journal-title":"J Immunol"},{"issue":"48","key":"2765_CR27","doi-asserted-by":"publisher","first-page":"20371","DOI":"10.1073\/pnas.0911573106","volume":"106","author":"M Gigoux","year":"2009","unstructured":"Gigoux M, Shang J, Pak Y, Xu M, Choe J, Mak TW, et al. Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2009;106(48):20371\u20136. https:\/\/doi.org\/10.1073\/pnas.0911573106 . PubMed PMID: 19915142; PubMed Central PMCID: PMC2787139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2765_CR28","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, et al. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discov. 2018;8(8):944\u201357. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1417 . PubMed PMID: 29891538; PubMed Central PMCID: PMC8092079.","journal-title":"Cancer Discov"},{"key":"2765_CR29","doi-asserted-by":"publisher","unstructured":"Kortleve D, Hammerl D, van Brakel M, Wijers R, Roelofs D, Kroese K, et al. TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer. Cancer Discov. 2024;22. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0168. PubMed PMID: 39172012.","DOI":"10.1158\/2159-8290.CD-24-0168"},{"issue":"3","key":"2765_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nbt1070","volume":"23","author":"Y Li","year":"2005","unstructured":"Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005;23(3):349\u201354. https:\/\/doi.org\/10.1038\/nbt1070 . PubMed PMID: 15723046.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2765_CR31","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/nar\/23.4.628","volume":"23","author":"Y Soneoka","year":"1995","unstructured":"Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995;23(4):628\u201333. https:\/\/doi.org\/10.1093\/nar\/23.4.628 . PubMed PMID: 7899083; PubMed Central PMCID: PMC306730.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2765_CR32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.cgt.7700477","volume":"9","author":"CHJ Lamers","year":"2002","unstructured":"Lamers CHJ, Willemsen RA, Luider BA, Debets R, Bolhuis RLH. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. 2002;9(7):613\u201323. https:\/\/doi.org\/10.1038\/sj.cgt.7700477 . PubMed PMID: 12082462.","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"2765_CR33","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/sj.gt.3300696","volume":"5","author":"ME Weijtens","year":"1998","unstructured":"Weijtens ME, Willemsen RA, Hart EH, Bolhuis RL. A retroviral vector system \u2018STITCH\u2019 in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 1998;5(9):1195\u2013203. https:\/\/doi.org\/10.1038\/sj.gt.3300696 . PubMed PMID: 9930320.","journal-title":"Gene Ther"},{"issue":"6","key":"2765_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/hgtb.2014.051","volume":"25","author":"CHJ Lamers","year":"2014","unstructured":"Lamers CHJ, van Steenbergen-Langeveld S, van Brakel M, Groot-van Ruijven CM, van Elzakker PMML, van Krimpen B, et al. T Cell Receptor-Engineered T Cells to Treat Solid Tumors: T Cell Processing Toward Optimal T Cell Fitness. Hum Gene Ther Methods. 2014;25(6):345\u201357. https:\/\/doi.org\/10.1089\/hgtb.2014.051 . PubMed PMID: 25423330; PubMed Central PMCID: PMC4268575.","journal-title":"Hum Gene Ther Methods"},{"issue":"1","key":"2765_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ymthe.2019.10.001","volume":"28","author":"LT Morton","year":"2020","unstructured":"Morton LT, Reijmers RM, Wouters AK, Kweekel C, Remst DFG, Pothast CR, et al. Simultaneous Deletion of Endogenous TCR\u03b1\u03b2 for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic. Mol Ther. 2020;28(1):64\u201374. https:\/\/doi.org\/10.1016\/j.ymthe.2019.10.001 . PubMed PMID: 31636040; PubMed Central PMCID: PMC6953894.","journal-title":"Mol Ther"},{"issue":"7643","key":"2765_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137. https:\/\/doi.org\/10.1038\/nature21405 . PubMed PMID: 28225754; PubMed Central PMCID: PMC5558614.","journal-title":"Nature"},{"issue":"12","key":"2765_CR37","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1084\/jem.185.12.2043","volume":"185","author":"S Pascolo","year":"1997","unstructured":"Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, P\u00e9rarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. 1997;185(12):2043\u201351. https:\/\/doi.org\/10.1084\/jem.185.12.2043.\u00a0PubMed PMID: 9182675; PubMed Central PMCID: PMC2196346.","journal-title":"J Exp Med"},{"key":"2765_CR38","doi-asserted-by":"publisher","unstructured":"Seynhaeve ALB, Hoving S, Schipper D, Vermeulen CE, de Wiel-Ambagtsheer G aan, van Tiel ST et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res. 2007;67(19):9455\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1599. PubMed PMID: 17909055.","DOI":"10.1158\/0008-5472.CAN-07-1599"},{"key":"2765_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fimmu.2013.00270","volume":"4","author":"N Schaft","year":"2013","unstructured":"Schaft N, Coccoris M, Drexhage J, Knoop C, de Vries IJM, Adema GJ, et al. An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8\u03b1 Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT. Front Immunol. 2013;4:270. https:\/\/doi.org\/10.3389\/fimmu.2013.00270 . PubMed PMID: 24027572; PubMed Central PMCID: PMC3762364.","journal-title":"Front Immunol"},{"issue":"17","key":"2765_CR40","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1074\/jbc.M115.707414","volume":"291","author":"V Bianchi","year":"2016","unstructured":"Bianchi V, Bulek A, Fuller A, Lloyd A, Attaf M, Rizkallah PJ, et al. A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen. J Biol Chem. 2016;291(17):8951\u20139. https:\/\/doi.org\/10.1074\/jbc.M115.707414 . PubMed PMID: 26917722; PubMed Central PMCID: PMC4861463.","journal-title":"J Biol Chem"},{"issue":"35","key":"2765_CR41","doi-asserted-by":"publisher","first-page":"32786","DOI":"10.1074\/jbc.M102498200","volume":"276","author":"MA Purbhoo","year":"2001","unstructured":"Purbhoo MA, Boulter JM, Price DA, Vuidepot AL, Hourigan CS, Dunbar PR, et al. The Human CD8 Coreceptor Effects Cytotoxic T Cell Activation and Antigen Sensitivity Primarily by Mediating Complete Phosphorylation of the T Cell Receptor \u03b6 Chain*. J Biol Chem. 2001;276(35):32786\u201392. https:\/\/doi.org\/10.1074\/jbc.M102498200.","journal-title":"J Biol Chem"},{"issue":"2","key":"2765_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1158\/1078-0432.CCR-19-0285","volume":"26","author":"D Hammerl","year":"2020","unstructured":"Hammerl D, Massink MPG, Smid M, van Deurzen CHM, Meijers-Heijboer HEJ, Waisfisz Q, et al. Clonality, Antigen Recognition, and Suppression of CD8\u2009+\u2009T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. Clin Cancer Res. 2020;26(2):505\u201317. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0285 . PubMed PMID: 31649042.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2765_CR43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.it.2022.03.006","volume":"43","author":"D Kortleve","year":"2022","unstructured":"Kortleve D, Coelho RML, Hammerl D, Debets R. Cancer germline antigens and tumor-agnostic CD8\u2009+\u2009T cell evasion. Trends Immunol. 2022;43(5):391\u2013403. https:\/\/doi.org\/10.1016\/j.it.2022.03.006.\u00a0 PubMed PMID: 35414484.","journal-title":"Trends Immunol"},{"issue":"4","key":"2765_CR44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.cell.2018.07.003","volume":"174","author":"N Chu","year":"2018","unstructured":"Chu N, Salguero AL, Liu AZ, Chen Z, Dempsey DR, Ficarro SB, et al. Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis. Cell. 2018;174(4):897\u2013e90714. https:\/\/doi.org\/10.1016\/j.cell.2018.07.003 . PubMed PMID: 30078705; PubMed Central PMCID: PMC6139374.","journal-title":"Cell"},{"issue":"23","key":"2765_CR45","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1002\/j.1460-2075.1996.tb01045.x","volume":"15","author":"DR Alessi","year":"1996","unstructured":"Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15(23):6541\u201351. PubMed PMID: 8978681; PubMed Central PMCID: PMC452479.","journal-title":"EMBO J"},{"key":"2765_CR46","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC. NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. https:\/\/doi.org\/10.1038\/sigtrans.2017.23.\u00a0 PubMed PMID: 29158945; PubMed Central PMCID: PMC5661633.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2765_CR47","doi-asserted-by":"publisher","first-page":"13464","DOI":"10.1038\/s41598-021-92941-2","volume":"11","author":"CM Su","year":"2021","unstructured":"Su CM, Wang L, Yoo D. Activation of NF-\u03baB and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2. Sci Rep. 2021;11(1):13464. https:\/\/doi.org\/10.1038\/s41598-021-92941-2.","journal-title":"Sci Rep"},{"issue":"2","key":"2765_CR48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1084\/jem.20082487","volume":"206","author":"J Kuball","year":"2009","unstructured":"Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med. 2009;206(2):463\u201375. https:\/\/doi.org\/10.1084\/jem.20082487.","journal-title":"J Exp Med"},{"issue":"11","key":"2765_CR49","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.4049\/jimmunol.0902055","volume":"184","author":"D Sommermeyer","year":"2010","unstructured":"Sommermeyer D, Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol. 2010;184(11):6223\u201331. https:\/\/doi.org\/10.4049\/jimmunol.0902055 . PubMed PMID: 20483785.","journal-title":"J Immunol"},{"issue":"12","key":"2765_CR50","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.4049\/jimmunol.143.12.4069","volume":"143","author":"C Geisler","year":"1989","unstructured":"Geisler C, Kuhlmann J, Rubin B. Assembly, intracellular processing, and expression at the cell surface of the human alpha beta T cell receptor\/CD3 complex. Function of the CD3-zeta chain. J Immunol. 1989;143(12):4069\u201377.","journal-title":"J Immunol"},{"issue":"23","key":"2765_CR51","doi-asserted-by":"publisher","first-page":"10619","DOI":"10.1073\/pnas.88.23.10619","volume":"88","author":"DJ Kappes","year":"1991","unstructured":"Kappes DJ, Tonegawa S. Surface expression of alternative forms of the TCR\/CD3 complex. Proc Natl Acad Sci. 1991;88(23):10619\u201323. https:\/\/doi.org\/10.1073\/pnas.88.23.10619.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2765_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/intimm\/3.4.359","volume":"3","author":"C Hall","year":"1991","unstructured":"Hall C, Berkhout B, Alarcon B, Sancho J, Wileman T, Terhorst C. Requirements for cell surface expression of the human TCR\/CD3 complex in non-T cells. Int Immunol. 1991;3(4):359\u201368. https:\/\/doi.org\/10.1093\/intimm\/3.4.359 . PubMed PMID: 1831654.","journal-title":"Int Immunol"},{"issue":"1","key":"2765_CR53","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41590-023-01665-0","volume":"25","author":"P Hern\u00e1ndez-L\u00f3pez","year":"2024","unstructured":"Hern\u00e1ndez-L\u00f3pez P, van Diest E, Brazda P, Heijhuurs S, Meringa A, van Hoorens L, et al. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells. Nat Immunol. 2024;25(1):88\u2013101. https:\/\/doi.org\/10.1038\/s41590-023-01665-0 . PubMed PMID: 38012415.","journal-title":"Nat Immunol"},{"issue":"5","key":"2765_CR54","doi-asserted-by":"publisher","first-page":"e002555","DOI":"10.1136\/jitc-2021-002555","volume":"9","author":"DG Tantalo","year":"2021","unstructured":"Tantalo DG, Oliver AJ, von Scheidt B, Harrison AJ, Mueller SN, Kershaw MH, et al. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. J Immunother Cancer. 2021;9(5):e002555. https:\/\/doi.org\/10.1136\/jitc-2021-002555 . PubMed PMID: 34035114; PubMed Central PMCID: PMC8154965.","journal-title":"J Immunother Cancer"},{"issue":"16","key":"2765_CR55","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1158\/1078-0432.CCR-11-0503","volume":"17","author":"CA Klebanoff","year":"2011","unstructured":"Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. Determinants of Successful CD8\u2009+\u2009T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice. Clin Cancer Res. 2011;17(16):5343\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0503.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2765_CR56","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1073\/pnas.86.6.1963","volume":"86","author":"BS Kwon","year":"1989","unstructured":"Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A. 1989;86(6):1963\u20137. https:\/\/doi.org\/10.1073\/pnas.86.6.1963.\u00a0 PubMed PMID: 2784565; PubMed Central PMCID: PMC286825.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2765_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2006.04.001","volume":"106","author":"T Fujita","year":"2006","unstructured":"Fujita T, Ukyo N, Hori T, Uchiyama T. Functional characterization of OX40 expressed on human CD8\u2009+\u2009T cells. Immunol Lett. 2006;106(1):27\u201333. https:\/\/doi.org\/10.1016\/j.imlet.2006.04.001.","journal-title":"Immunol Lett"},{"issue":"6","key":"2765_CR58","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","volume":"140","author":"O Takeuchi","year":"2010","unstructured":"Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation. Cell. 2010;140(6):805\u201320. https:\/\/doi.org\/10.1016\/j.cell.2010.01.022.","journal-title":"Cell"},{"issue":"26","key":"2765_CR59","doi-asserted-by":"publisher","first-page":"27199","DOI":"10.1074\/jbc.M403107200","volume":"279","author":"MI Wickremasinghe","year":"2004","unstructured":"Wickremasinghe MI, Thomas LH, O\u2019Kane CM, Uddin J, Friedland JS. Transcriptional mechanisms regulating alveolar epithelial cell-specific CCL5 secretion in pulmonary tuberculosis. J Biol Chem. 2004;279(26):27199\u2013210. https:\/\/doi.org\/10.1074\/jbc.M403107200. PubMed PMID: 15117956.","journal-title":"J Biol Chem"},{"issue":"4903","key":"2765_CR60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1126\/science.2497518","volume":"244","author":"B Hoyos","year":"1989","unstructured":"Hoyos B, Ballard DW, B\u00f6hnlein E, Siekevitz M, Greene WC. Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science. 1989;244(4903):457\u201360. https:\/\/doi.org\/10.1126\/science.2497518 . PubMed PMID: 2497518.","journal-title":"Science"},{"issue":"5","key":"2765_CR61","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1128\/mcb.10.5.2327-2334.1990","volume":"10","author":"TA Libermann","year":"1990","unstructured":"Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol. 1990;10(5):2327\u201334. https:\/\/doi.org\/10.1128\/mcb.10.5.2327-2334.1990. PubMed PMID: 2183031; PubMed Central PMCID: PMC360580.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2765_CR62","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1128\/mcb.10.4.1498-1506.1990","volume":"10","author":"MA Collart","year":"1990","unstructured":"Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol. 1990;10(4):1498\u2013506. https:\/\/doi.org\/10.1128\/mcb.10.4.1498-1506.1990.\u00a0 PubMed PMID: 2181276; PubMed Central PMCID: PMC362253.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2765_CR63","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4049\/jimmunol.1203485","volume":"191","author":"J Li","year":"2013","unstructured":"Li J, Heinrichs J, Leconte J, Haarberg K, Semple K, Liu C, et al. Phosphatidylinositol 3-Kinase\u2013Independent Signaling Pathways Contribute to ICOS-Mediated T Cell Costimulation in Acute Graft-Versus-Host Disease in Mice. J Immunol. 2013;191(1):200\u20137. https:\/\/doi.org\/10.4049\/jimmunol.1203485 . PubMed PMID: 23729441; PubMed Central PMCID: PMC4318500.","journal-title":"J Immunol"},{"issue":"12","key":"2765_CR64","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1158\/2326-6066.CIR-20-0034","volume":"8","author":"RCA Sainson","year":"2020","unstructured":"Sainson RCA, Thotakura AK, Kosmac M, Borhis G, Parveen N, Kimber R, et al. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression. Cancer Immunol Res. 2020;8(12):1568\u201382. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0034 . PubMed PMID: 32999002.","journal-title":"Cancer Immunol Res"},{"issue":"49","key":"2765_CR65","doi-asserted-by":"publisher","first-page":"45686","DOI":"10.1074\/jbc.M108509200","volume":"276","author":"G Richter","year":"2001","unstructured":"Richter G, Hayden-Ledbetter M, Irgang M, Ledbetter JA, Westermann J, K\u00f6rner I, et al. Tumor Necrosis Factor-\u03b1 Regulates the Expression of Inducible Costimulator Receptor Ligand on CD34\u2009+\u2009Progenitor Cells during Differentiation into Antigen Presenting Cells*. J Biol Chem. 2001;276(49):45686\u201393. https:\/\/doi.org\/10.1074\/jbc.M108509200.","journal-title":"J Biol Chem"},{"issue":"7","key":"2765_CR66","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.4049\/jimmunol.0800758","volume":"182","author":"JM Odegard","year":"2009","unstructured":"Odegard JM, DiPlacido LD, Greenwald L, Kashgarian M, Kono DH, Dong C, et al. ICOS Controls Effector Function but Not Trafficking Receptor Expression of Kidney-Infiltrating Effector T Cells in Murine Lupus. J Immunol. 2009;182(7):4076\u201384. https:\/\/doi.org\/10.4049\/jimmunol.0800758 . PubMed PMID: 19299705; PubMed Central PMCID: PMC2746004.","journal-title":"J Immunol"},{"key":"2765_CR67","doi-asserted-by":"publisher","unstructured":"Alves GF, Stoppa I, Aimaretti E, Monge C, Mastrocola R, Porchietto E, et al. ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.992614.","DOI":"10.3389\/fimmu.2022.992614"},{"issue":"8","key":"2765_CR68","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.4049\/jimmunol.166.8.4943","volume":"166","author":"JL Riley","year":"2001","unstructured":"Riley JL, Blair PJ, Musser JT, Abe R, Tezuka K, Tsuji T, et al. ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement1. J Immunol. 2001;166(8):4943\u20138. https:\/\/doi.org\/10.4049\/jimmunol.166.8.4943.","journal-title":"J Immunol"},{"issue":"2","key":"2765_CR69","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1084\/jem.20021305","volume":"197","author":"Y Harada","year":"2003","unstructured":"Harada Y, Ohgai D, Watanabe R, Okano K, Koiwai O, Tanabe K, et al. A single amino acid alteration in cytoplasmic domain determines IL-2 promoter activation by ligation of CD28 but not inducible costimulator (ICOS). J Exp Med. 2003;197(2):257\u201362. https:\/\/doi.org\/10.1084\/jem.20021305 . PubMed PMID: 12538664; PubMed Central PMCID: PMC2193818.","journal-title":"J Exp Med"},{"issue":"6763","key":"2765_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/35005523","volume":"402","author":"A Hutloff","year":"1999","unstructured":"Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;402(6763):21\u20134. https:\/\/doi.org\/10.1038\/35005523.","journal-title":"Nature"},{"issue":"10","key":"2765_CR71","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/intimm\/12.10.1439","volume":"12","author":"SK Yoshinaga","year":"2000","unstructured":"Yoshinaga SK, Zhang M, Pistillo J, Horan T, Khare SD, Miner K, et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int Immunol. 2000;12(10):1439\u201347. https:\/\/doi.org\/10.1093\/intimm\/12.10.1439 . PubMed PMID: 11007762.","journal-title":"Int Immunol"},{"issue":"6763","key":"2765_CR72","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/45582","volume":"402","author":"SK Yoshinaga","year":"1999","unstructured":"Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature. 1999;402(6763):827\u201332. https:\/\/doi.org\/10.1038\/45582.","journal-title":"Nature"},{"issue":"2","key":"2765_CR73","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ni.1687","volume":"10","author":"SG Park","year":"2009","unstructured":"Park SG, Schulze-Luehrman J, Hayden MS, Hashimoto N, Ogawa W, Kasuga M, et al. Phosphoinositide-dependent kinase 1 integrates T cell receptor and CD28 co-receptor signaling to effect NF-\u03baB induction and T cell activation. Nat Immunol. 2009;10(2):158\u201366. https:\/\/doi.org\/10.1038\/ni.1687 . PubMed PMID: 19122654; PubMed Central PMCID: PMC2768497.","journal-title":"Nat Immunol"},{"issue":"21","key":"2765_CR74","doi-asserted-by":"publisher","first-page":"12779","DOI":"10.1074\/jbc.273.21.12779","volume":"273","author":"S Montaner","year":"1998","unstructured":"Montaner S, Perona R, Saniger L, Lacal JC. Multiple Signalling Pathways Lead to the Activation of the Nuclear Factor \u03baB by the Rho Family of GTPases *. J Biol Chem. 1998;273(21):12779\u201385. https:\/\/doi.org\/10.1074\/jbc.273.21.12779.","journal-title":"J Biol Chem"},{"issue":"3","key":"2765_CR75","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.4049\/jimmunol.181.3.1969","volume":"181","author":"C Fos","year":"2008","unstructured":"Fos C, Salles A, Lang V, Carrette F, Audebert S, Pastor S, et al. ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse. J Immunol. 2008;181(3):1969\u201377. https:\/\/doi.org\/10.4049\/jimmunol.181.3.1969.\u00a0 PubMed PMID: 18641334.","journal-title":"J Immunol"},{"issue":"2","key":"2765_CR76","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41423-018-0183-z","volume":"17","author":"Z Wan","year":"2020","unstructured":"Wan Z, Shao X, Ji X, Dong L, Wei J, Xiong Z, et al. Transmembrane domain-mediated Lck association underlies bystander and costimulatory ICOS signaling. Cell Mol Immunol. 2020;17(2):143\u201352. https:\/\/doi.org\/10.1038\/s41423-018-0183-z.","journal-title":"Cell Mol Immunol"},{"key":"2765_CR77","doi-asserted-by":"publisher","unstructured":"Guedan S, Posey AD, Shaw C, Wing A, Da T, Patel PR et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3(1):e96976, 96976. https:\/\/doi.org\/10.1172\/jci.insight.96976. PubMed PMID: 29321369; PubMed Central PMCID: PMC5821198.","DOI":"10.1172\/jci.insight.96976"},{"issue":"1","key":"2765_CR78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4110\/in.2014.14.1.14","volume":"14","author":"SH Park","year":"2014","unstructured":"Park SH, Cho G, Park SG. NF-\u03baB Activation in T Helper 17 Cell Differentiation. Immune Netw. 2014;14(1):14\u201320. https:\/\/doi.org\/10.4110\/in.2014.14.1.14.\u00a0 PubMed PMID: 24605076; PubMed Central PMCID: PMC3942503.","journal-title":"Immune Netw"},{"key":"2765_CR79","doi-asserted-by":"publisher","unstructured":"Molinero LL, Cubre A, Mora-Solano C, Wang Y, Alegre ML. T cell receptor\/CARMA1\/NF-\u03baB signaling controls T-helper (Th) 17 differentiation. Proceedings of the National Academy of Sciences. 2012;109(45):18529\u201334. https:\/\/doi.org\/10.1073\/pnas.1204557109","DOI":"10.1073\/pnas.1204557109"},{"issue":"7","key":"2765_CR80","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.ymthe.2023.04.010","volume":"31","author":"MM Wyatt","year":"2023","unstructured":"Wyatt MM, Huff LW, Nelson MH, Neal LR, Medvec AR, Rangel Rivera GO, et al. Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells. Mol Ther. 2023;31(7):2120\u201331. https:\/\/doi.org\/10.1016\/j.ymthe.2023.04.010.\u00a0PubMed PMID: 37081789; PubMed Central PMCID: PMC10362414.","journal-title":"Mol Ther"},{"issue":"55","key":"2765_CR81","doi-asserted-by":"publisher","first-page":"55ra78","DOI":"10.1126\/scitranslmed.3000448","volume":"2","author":"CM Paulos","year":"2010","unstructured":"Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, et al. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med. 2010;2(55):55ra78. https:\/\/doi.org\/10.1126\/scitranslmed.3000448 . PubMed PMID: 20980695; PubMed Central PMCID: PMC6282816.","journal-title":"Sci Transl Med"},{"issue":"10","key":"2765_CR82","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc3322","volume":"12","author":"L Gattinoni","year":"2012","unstructured":"Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012;12(10):671\u201384. https:\/\/doi.org\/10.1038\/nrc3322.\u00a0PubMed PMID: 22996603; PubMed Central PMCID: PMC6352980.","journal-title":"Nat Rev Cancer"},{"key":"2765_CR83","doi-asserted-by":"publisher","unstructured":"Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight. 2017;2(23):e95103, 95103. https:\/\/doi.org\/10.1172\/jci.insight.95103. PubMed PMID: 29212954; PubMed Central PMCID: PMC5752304.","DOI":"10.1172\/jci.insight.95103"},{"issue":"10","key":"2765_CR84","doi-asserted-by":"publisher","first-page":"e1488565","DOI":"10.1080\/2162402X.2018.1488565","volume":"7","author":"CM Mousset","year":"2018","unstructured":"Mousset CM, Hobo W, Ji Y, Fredrix H, De Giorgi V, Allison RD, et al. Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8\u2009+\u2009T cells for adoptive immunotherapy. Oncoimmunology. 2018;7(10):e1488565. https:\/\/doi.org\/10.1080\/2162402X.2018.1488565. PubMed PMID: 30288356; PubMed Central PMCID: PMC6169586.","journal-title":"Oncoimmunology"},{"issue":"5","key":"2765_CR85","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.3390\/ijms23052878","volume":"23","author":"Y Kaminskiy","year":"2022","unstructured":"Kaminskiy Y, Melenhorst JJ. STAT3 Role in T-Cell Memory Formation. Int J Mol Sci. 2022;23(5):2878. https:\/\/doi.org\/10.3390\/ijms23052878.\u00a0 PubMed PMID: 35270020; PubMed Central PMCID: PMC8910982.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2765_CR86","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1084\/jem.20041133","volume":"201","author":"P Delgado","year":"2005","unstructured":"Delgado P, Alarc\u00f3n B. An orderly inactivation of intracellular retention signals controls surface expression of the T cell antigen receptor. J Exp Med. 2005;201(4):555\u201366. https:\/\/doi.org\/10.1084\/jem.20041133 . PubMed PMID: 15728236; PubMed Central PMCID: PMC2213059.","journal-title":"J Exp Med"},{"issue":"7","key":"2765_CR87","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/j.1460-2075.1994.tb06434.x","volume":"13","author":"MP Schutze","year":"1994","unstructured":"Schutze MP, Peterson PA, Jackson MR. An N-terminal double-arginine motif maintains type II membrane proteins in the endoplasmic reticulum. EMBO J. 1994;13(7):1696. https:\/\/doi.org\/10.1002\/j.1460-2075.1994.tb06434.x.\u00a0 PubMed PMID: 8157008.","journal-title":"EMBO J"},{"issue":"2","key":"2765_CR88","doi-asserted-by":"publisher","first-page":"e20201966","DOI":"10.1084\/jem.20201966","volume":"219","author":"M Shakiba","year":"2021","unstructured":"Shakiba M, Zumbo P, Espinosa-Carrasco G, Menocal L, D\u00fcndar F, Carson SE, et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J Exp Med. 2021;219(2):e20201966. https:\/\/doi.org\/10.1084\/jem.20201966.","journal-title":"J Exp Med"},{"issue":"9","key":"2765_CR89","doi-asserted-by":"publisher","first-page":"e1000482","DOI":"10.1371\/journal.pbio.1000482","volume":"8","author":"JE Slansky","year":"2010","unstructured":"Slansky JE, Jordan KR. The Goldilocks Model for TCR\u2014Too Much Attraction Might Not Be Best for Vaccine Design. PLoS Biol. 2010;8(9):e1000482. https:\/\/doi.org\/10.1371\/journal.pbio.1000482.","journal-title":"PLoS Biol"},{"key":"2765_CR90","doi-asserted-by":"publisher","unstructured":"Kortleve D, van Brakel M, Wijers R, Debets R, Hammerl D, Gene Engineering T. Cells with T-Cell Receptor for Adoptive Therapy. Immunogenetics: Methods and Protocols. Humana; 2022. https:\/\/doi.org\/10.1007\/978-1-0716-2115-8_13.\u00a0 PubMed PMID: 35622329.","DOI":"10.1007\/978-1-0716-2115-8_13"},{"issue":"1","key":"2765_CR91","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.immuni.2021.11.017","volume":"55","author":"C Peng","year":"2022","unstructured":"Peng C, Huggins MA, Wanhainen KM, Knutson TP, Lu H, Georgiev H, et al. Engagement of the costimulatory molecule ICOS in tissues promotes establishment of CD8\u2009+\u2009tissue-resident memory T cells. Immunity. 2022;55(1):98\u2013e1145. https:\/\/doi.org\/10.1016\/j.immuni.2021.11.017.\u00a0PubMed PMID: 34932944; PubMed Central PMCID: PMC8755622.","journal-title":"Immunity"},{"key":"2765_CR92","doi-asserted-by":"publisher","unstructured":"Damei I, Trickovic T, Mami-Chouaib F, Corgnac S. Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1205984.","DOI":"10.3389\/fimmu.2023.1205984"},{"issue":"4","key":"2765_CR93","doi-asserted-by":"publisher","first-page":"e20201605","DOI":"10.1084\/jem.20201605","volume":"218","author":"K Ok\u0142a","year":"2021","unstructured":"Ok\u0142a K, Farber DL, Zou W. Tissue-resident memory T cells in tumor immunity and immunotherapy. J Exp Med. 2021;218(4):e20201605. https:\/\/doi.org\/10.1084\/jem.20201605 . PubMed PMID: 33755718; PubMed Central PMCID: PMC7992502.","journal-title":"J Exp Med"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02765-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02765-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02765-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:02:34Z","timestamp":1791489754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02765-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2765"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02765-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mice experiments were approved by the Experimental Animal Committee of the Erasmus MC Cancer Institute and carried out in accordance with institutional and national guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"<b>Consent for publication<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexandre Marraffa, Cor Berrevoets and Reno Debets report pending patent P136875EP00. Dora Hammerl reports grants from the Dutch Cancer Society and Health Holland Public-private partnership as well as pending patent P128827EP00. Rachel Abbott reports a grant from Health Holland Public-private partnership as well as support from Swanbridge Capital, Van Herk Ventures, Thuja Capital and Innovation Quarter. Reno Debets reports grants from the Erasmus MC Daniel den Hoed Foundation, the Dutch Cancer Society, Health Holland Public-private partnership and the EU, support from MSD, Bayer, and Pan Cancer T, as well as the pending patents P128827EP00 and P130556EP00. The other authors have no disclosures to report.","order":3,"name":"Ethics","label":"<b>Competing interests<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"216"}}